NCT01689207View on ClinicalTrials.gov

To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)

PHASE1CompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Complicated InfectionBacterial Infections
Interventions
DRUG

Avibactam (AVI)

PART A: AVI IV infusion

DRUG

Aztreonam (ATM)

PART A: ATM IV infusion

DRUG

combination of Aztreonam - Avibactam (ATM-AVI)

PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.

DRUG

Placebo

PART A, PART B, PART C: matching placebo IV infusions

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01689207 - To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) | Biotech Hunter | Biotech Hunter